Artivion Completes Convertible Notes Exchange Agreement

Artivion ( (AORT) ) has issued an update.

On May 28, 2025, Artivion, Inc. announced the completion of transactions related to privately negotiated exchange agreements with holders of its 4.250% Convertible Senior Notes due 2025. These transactions involved exchanging approximately $99.54 million in principal amount of notes for 4,334,347 shares of common stock and a cash payment of $1.7 million for accrued interest. This move effectively retires the convertible notes, significantly reducing the company’s debt and enhancing its financial flexibility, as stated by CEO Pat Mackin.

The most recent analyst rating on (AORT) stock is a Buy with a $32.00 price target. To see the full list of analyst forecasts on Artivion stock, see the AORT Stock Forecast page.

Spark’s Take on AORT Stock

According to Spark, TipRanks’ AI Analyst, AORT is a Neutral.

Artivion is on a cautious growth path with strong revenue momentum and positive earnings call guidance. However, profitability challenges and valuation concerns due to negative earnings limit the stock’s attractiveness. Technical indicators show strong momentum but caution is advised due to overbought conditions.

To see Spark’s full report on AORT stock, click here.

More about Artivion

Headquartered in suburban Atlanta, Georgia, Artivion, Inc. is a medical device company focused on developing solutions for cardiac and vascular surgeons, particularly in treating aortic diseases. The company offers products such as aortic stent grafts, surgical sealants, On-X mechanical heart valves, and implantable cardiac and vascular human tissues, and markets them in over 100 countries worldwide.

Average Trading Volume: 499,941

Technical Sentiment Signal: Strong Buy

Current Market Cap: $1.25B

For a thorough assessment of AORT stock, go to TipRanks’ Stock Analysis page.